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Disclaimer: This guideline is designed primarily as an educational resource for medical geneticists and other health care
providers to help them provide quality medical genetic services. Adherence to this guideline does not necessarily assure a
successful medical outcome. This guideline should not be considered inclusive of all proper procedures and tests or exclusive
of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any
specificprocedureortest,thegeneticistshouldapplyhisorherownprofessionaljudgmenttothespecificclinicalcircumstances
presentedbytheindividualpatientorspecimen.Itmaybeprudent,however,todocumentinthepatient’srecordtherationale
for any significant deviation from this guideline.
The following are the recommendations of the American Col-
lege of Medical Genetics (ACMG) Professional Practice and
Guidelines Committee, convened to assist health care profession-
als in making decisions regarding genetic diagnosis and testing.
The purpose of this document is to provide a brief overview of
fragile X syndrome (FXS), and to make recommendations that
canserveasgeneralguidelinestoaidcliniciansinmakingreferrals
for diagnostic and carrier testing for this condition. Fragile X
syndromeisthemostcommoncauseofinheritedmentalretarda-
tion and is caused by a mutation in the X-linked FMR1 gene.




supersede the 1994 ACMG statement of the same name.
INTRODUCTION
Fragile X syndrome is the most common cause of inherited
mental retardation and is due to a mutation in the X-linked
FMR1 gene. Males with fragile X syndrome almost always ex-
hibit mental retardation, usually in the moderate range, and
often have characteristic physical features and behavior. Since
themutationisX-linked,malesaremoreseverelyaffectedthan
females.Thus,affectedfemalestendtohavemildmentalretar-
dation, and have variable associated physical features. (For re-
viewofthefeaturesoffragileXsyndrome,identificationofthe
gene, and its inheritance pattern, see Warren and Sherman
(2001)1 and Hagerman and Hagerman (2002)).2
The mutation leading to over 98% of cases of fragile X
syndrome is an expansion of an unstable CGG repeat se-
quence located in the 5’ untranslated region (UTR) of the
FMR1 gene.3,4 There are essentially four allelic forms of the
gene with respect to repeat length. They are referred to as
common, “gray zone” or intermediate, premutation, and
fullmutation.Theassociatedrepeatsizesforeachgroupare
not well-defined and, as such, complicate genetic counsel-
ing. The full mutation form of the FMR1 gene consists of
over 200 repeats and is abnormally hypermethylated. Con-
sequently, the gene is silenced and no mRNA is produced.
The lack of the gene product, FMRP, an RNA-binding pro-
tein, is responsible for the mental retardation.5 Approxi-
mately 1/4000 males have fragile X syndrome and, by infer-
ence, about 1/8000 females have significant features of the
syndrome (for review, see Crawford et al. (2001)).6 Premu-
tationallelesaredefinedaslong,unmethylatedrepeattracks
that are unstably transmitted from parent to child. Approx-
imately 1/350 females and 1/1000 males carry premutation
alleles in the range of 61–200 repeats. However, this repeat
range for premutation alleles is probably too narrowly de-
fined, since unstable alleles with 50 to 60 repeats are some-
times identified in the older generations of families with
fragile X syndrome and clearly are “permutation” alleles.
Alleles in the intermediate range (41–60) are usually de-
fined by repeat size only. That is, they usually are not asso-
ciated with known unstable transmission to a full mutation
and/orarelativewithfragileXsyndrome.Instabilitymayor
may not be characteristic of the allele and depends on fac-
tors related to the repeat structure (i.e., interruption of
CGG repeats by an AGG sequence) and trans-acting factors
notyetdefined.7–9Thus,thedefinitionsofpremutationand
intermediateallelesareblurred.Mostoftenapremutationis
clinically reported when it is  55 repeats. Overall, high
repeat number tracks (41–199) are carried by about 4% of
males and 8% of females of Northern European descent.
Theprevalenceissimilarinmostotherethnic/racialgroups,
although there is some variation among populations.10–11
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the FMR1 gene were thought to be restricted to those with
the full mutation (hence the term “full”), namely, overt
mental retardation. However, the unmethlyated, long CGG
repeat track found in premutation carriers has been associ-
ated with specific phenotypes unrelated to fragile X syn-
drome and unrelated to full mutation carriers. One well
recognized consequence for women who carry the premu-
tation allele is an increased risk for premature ovarian fail-
ure (POF), clinically defined as the cessation of menses be-
fore the age of 40. Among women who carry the
premutation, approximately 21% have POF compared to
only 1% in the general population, or a relative risk of 21.12
Furthermore, approximately 2% and 14% of women with
isolated POF and familial POF, respectively, carry the pre-
mutation allele. This high carrier frequency compares with
0.3% in the general population. The etiology of the ovarian
failure and the risk factors associated with the FMR1 gene
are under investigation.
More recently, a significant increase in the risk for a late
onset neurodegenerative disorder with tremor/ataxia syn-
drome(FXTAS)hasbeenidentifiedinmenwhocarrythepre-
mutation,andinasmallerproportionofwomen.13–15Thepri-
mary clinical symptoms are cerebellar ataxia and intention
tremor. Other documented symptoms include cognitive defi-
cits such as short-term memory loss, executive function defi-
cits, cognitive decline, parkinsonism, peripheral neuropathy,
lower limb proximal muscle weakness and autonomic
dysfunction.14 Initial studies indicate a penetrance of com-
bined tremor and ataxia among men ages 50 years or more
with the premutation of about 20–40%.14–17 Overall, these
men have an estimated 13-fold increase in these symptoms
compared with noncarriers.15 However, more research is
neededtoaccuratelydefinetheage-relatedpenetranceandrel-
ative risks for genetic counseling purposes.
TheuniqueinheritancepatternofthisX-linkedmutation
leads to some sensitive issues related to an individual’s
knowledge of his or her own carrier status as well as cogni-
zance of mutation status in other family members. Most
often, the fragile X mutation segregating in a family is iden-
tifiedthroughachildwithfragileXsyndromeduetothefull
mutation, with symptoms such as developmental delay or
mental retardation. Thus, premutation carrier status asso-
ciatedwithlateonsetdisordersmaybeinadvertentlyuncov-
ered in an individual who is tested as part of a family study.
For late onset disorders such as these, ethical issues arise as
to whether or not a given individual wishes to know his or
her carrier status. As health professionals become more
aware of the premutation-associated phenotypes of prema-
ture ovarian failure and FXTAS, more families are likely to
be identified under other circumstances.
In general, the fragile X mutation follows the traditional
rules of X-linked inheritance: Half of the offspring of carrier
mothers will receive the mutation and all the daughters but
none of the sons of carrier fathers receive the mutation. How-
ever,theriskofexpansionoftheCGGrepeatsinapremutation
allele to a full mutation overlays the transmission pattern of
this syndrome. Expansion of the premutation to the full mu-
tation during transmission through a carrier woman is positively
correlated with the size of the woman’s repeat.9 The smallest re-
peat size to expand to a full mutation in one generation is 59
repeats.9 The risk of expansion to the full mutation from carrier
men to their daughters is rare, but has been reported.18 That is,
premutation males pass on the premutation to their daughters,
typically with only small expansions or contractions.
Prediction of the severity of the symptoms of fragile X syn-
drome is limited. Severity tends not to be influenced by the
number of repeats within a full mutation allele, since once the
full mutation allele is over 200 repeats and is methylated, no
geneproductismade.Aminorityofmaleswithafullmutation
have some alleles that are unmethylated; they are known as
“methylation mosaics.” Such alleles may produce FMRP, al-
though at lower levels than low repeat alleles, presumably due
to translation inefficiency.19 In addition, there are males who
are mosaic for pre- and full mutation alleles. Males with these
mosaic patterns are less severely affected, on average, than
those with only full mutation alleles. However, the range of
severity overlaps. For females who carry the full mutation, the
percentage of active X chromosomes with the normal repeat
allele compared to the full mutation allele can modify the se-
verity of the symptoms, as expected for any X-linked condi-
tion.However,itisdifficulttopredictseverityforanindividual
carrier based on this activation ratio. On average, about one-
third to one-half of females who carry the full mutation is
significantly affected with fragile X syndrome.
DNA studies are used to test for fragile X syndrome. Geno-
types of individuals with symptoms of FXS and individuals at
riskforcarryingthemutationcanbedeterminedbyexamining
the size of the trinucleotide repeat segment and the methyl-
ationstatusoftheFMR1gene.Twomainapproachesareused:
polymerase chain reaction (PCR) and Southern blot analysis.
PCRanalysisutilizesflankingprimerstoamplifyafragmentof
DNA spanning the repeat region. Thus, the sizes of the PCR
products are indicative of the approximate number of repeats
present in each allele of the individual being tested. The effi-
ciencyofthePCRreactionisinverselyrelatedtothenumberof
CGG repeats, so large mutations are more difficult to amplify
and may fail to yield a detectable product in the PCR assay.
This, and the fact that no information is obtained about the
FMR1 methylation status, are limitations of the PCR ap-
proach. On the other hand, PCR analysis permits accurate siz-
ing of alleles in the normal, the “gray zone,” and the premuta-
tion size ranges on small amounts of DNA in a relatively short
turnaround time. Also, the assay is not affected by skewed X-
chromosome inactivation.
FMR1 analysis by Southern blotting allows a crude measure
of the size of the repeat segments and an accurate assessment
of the methylation status to be assayed simultaneously. A
methylation-sensitive restriction enzyme that fails to cleave
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and unmethylated alleles. Southern blot analysis is more
labor intensive than PCR and requires larger quantities of
genomic DNA. Southern blot analysis accurately detects al-
leles in all size ranges, but precise sizing is not possible.
Furthermore, highly skewed inactivation of the X-chromo-
some harboring the premutation could lead to the lack of
resolution of the premutation allele. Laboratories should
have both methods available and perform the types of anal-
ysis or combination of analyses that are most appropriate
under the clinical circumstances.
In a small number of individuals with FXS, mechanisms
other than trinucleotide expansion, such as deletion or point
mutation, are responsible for the syndrome. In these cases,
linkage studies, cytogenetic, sequencing and/or assays de-
signed to identify rare mutations and deletions may provide
important information for relatives.
RECOMMENDATIONS FOR DIAGNOSTIC TESTING
Thepurposeoftheserecommendationsistoprovidegeneral
guidelines to aid clinicians in making referrals for testing the
repeat region of the FMR1 gene.
Individuals for Whom Testing Should Be Considered
Fragile X syndrome:
● Individuals of either sex with mental retardation, develop-
mentaldelay,orautism,especiallyiftheyhave(a)anyphys-
icalorbehavioralcharacteristicsoffragileXsyndrome,(b)a
family history of fragile X syndrome, or (c) male or female
relatives with undiagnosed mental retardation.
● Individualsseekingreproductivecounselingwhohave(a)
a family history of fragile X syndrome or (b) a family
history of undiagnosed mental retardation.
● Fetuses of known carrier mothers.
● Affected individuals or their relatives in the context of a
positive cytogenetic fragile X test result who are seeking
further counseling related to the risk of carrier status
among themselves or their relatives. The cytogenetic test
wasusedpriortotheidentificationoftheFMR1geneand
is significantly less accurate than the current DNA test.
DNA testing on such individuals is warranted to accu-
rately identify premutation carriers and to distinguish
premutation from full mutation carrier women.
Ovarian dysfunction:
● Womenwhoareexperiencingreproductiveorfertilityprob-
lems associated with elevated follicle stimulating hormone
(FSH) levels, especially if they have (a) a family history of
premature ovarian failure, (b) a family history of fragile X
syndrome, or (c) male or female relatives with undiagnosed
mental retardation.
Tremor/ataxia syndrome:
● Men and women who are experiencing late onset inten-
tion tremor and cerebellar ataxia of unknown origin, es-
pecially if they have (a) a family history of movement
disorders, (b) a family history of fragile X syndrome, or
(c) male or female relatives with undiagnosed mental re-
tardation.
Common Problems That Occur with the FMR1 Diagnostic Test
ThereareseveralissuesrelatedtotheFMR1DNAtestresults
that should be described. A difficult situation occurs when a
premutation allele is identified in a patient who has been re-
ferredbecauseofsymptomsofthefragileXsyndrome,primar-
ily developmental delay or mental retardation. There are sev-
eral explanations for this finding: 1) the symptoms and the
premutation carrier status occur together by chance; 2) the
phenotype is caused by the premutation allele; 3) the individ-
ual is a mosaic pre/full mutation carrier and the full mutation
allelecannotbedetectedinperipheralblood.Ifthealleleiden-
tifiedislarge(100repeats),thethirdexplanationmaybethe
most viable, especially if the parent of the patient also carries a
large pre or full mutation allele. The first and second explana-
tions are hard to distinguish and research is ongoing to deter-
mine if the premutation allele is responsible for overt symp-
toms of the fragile X syndrome.
Identification of alleles in the gray zone can also be prob-
lematic in terms of establishing the risk for expansion in
future generations. One method to determine instability is
to obtain biological samples from other family members to ex-
amine stability of the allele during transmission from parent to
offspring.
Lastly, carriers with pre/full mosaic pattern are especially
difficult to identify with just one DNA method. PCR testing
couldidentifythepremutation,butnotthefullmutation,leading
toadifferentriskassessmentforthefragileXsyndrome,FXTASor
POF. Thus, in a clinical setting, it may be prudent to conduct
Southern blot analysis even if a premutation allele is identified.
POPULATION SCREENING
Population carrier screening is not recommended at this
timeexceptaspartofawell-definedclinicalresearchprotocol.
While the DNA test is very accurate, it is important to ensure
that effective means are in place to adequately counsel tested
populations about the meaning and implications of these re-
sults. The nature of different phenotypes associated with the
FMR1 mutation in its premutation and full mutation forms
andtheinheritancepatternarecomplex.Furthermore,theap-
proach to genetic counseling for different phenotypes includ-
ing early onset disorder of mental retardation, adult onset of
premature ovarian failure, and a late onset disorder associated
withneurodegeneration,allwithinthesamefamilyhasnotyet
been addressed at a clinical level much less a population
screening level. Clearly, considerable work must be done be-
fore instituting general population screening.
Sherman et al.
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● DNA analysis is the method of choice if one is testing
specifically for fragile X syndrome and associated trinu-
cleotide repeat expansion in the FMR1 gene.
● Forisolatedcognitiveimpairment,DNAanalysisforfrag-
ile X syndrome should be performed as part of a compre-
hensive genetic evaluation that includes routine cytoge-
netic analysis. Cytogenetic studies are critical, since
constitutional chromosome abnormalities have been
identified as frequently or more frequently than fragile X
mutations in mentally retarded individuals referred for
fragile X testing.
● For individuals who are at risk due to an established fam-
ily history of fragile X syndrome, DNA testing alone is
sufficient. If the diagnosis of the affected relative was
based on previous cytogenetic testing for fragile X syn-
drome, at least one affected relative should have DNA
testing.
● Prenatal testing of a fetus should be offered when the
mother is a known carrier to determine whether the fetus
inheritedthenormalormutantFMR1gene.IdeallyDNA
testing should be performed on cultured amniocytes ob-
tained by amniocentesis after 15 weeks’ gestation. DNA
testing can be performed on chorionic villi obtained by
CVS at 10 to 12 weeks’ gestation, but the results must be
interpreted with caution because the methylation status
oftheFMR1geneisoftennotyetestablishedinchorionic
villi at the time of sampling. A follow-up amniocentesis
may be necessary to resolve an ambiguous result.
● If a woman has ovarian failure before the age of 40, DNA
testing for premutation size alleles should be considered
as part of the infertility evaluation and prior to in vitro
fertilization.
● If a patient has cerebellar ataxia and intentional tremor,
DNA testing for premutation size alleles, especially
among men, should be considered as part of the diagnos-
tic evaluation.
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